Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HR positive • HER-2 negative
|
DetermaIO™
|
Keytruda (pembrolizumab) • paclitaxel